This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Afatinib With CT and RT for EGFR-Mutant NSCLC

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by Lecia V. Sequist, Massachusetts General Hospital
Information provided by (Responsible Party):
Lecia V. Sequist, Massachusetts General Hospital Identifier:
First received: March 5, 2012
Last updated: March 10, 2017
Last verified: March 2017
March 5, 2012
March 10, 2017
April 2012
December 2017   (Final data collection date for primary outcome measure)
Response Rate [ Time Frame: 2 years ]
Assess the response rate to induction afatinib.
Same as current
Complete list of historical versions of study NCT01553942 on Archive Site
  • 2 Year Progression-Free Survival [ Time Frame: 2 years ]
    Estimate the 2-year progression-free survival (PFS)
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 2 years ]
    Describe the number of patients that have side effects of various types from the study treatment
  • Unresectable Disease Converted to Operable Cases [ Time Frame: 2 years ]
    Estimate the proportion of patients with initially unresectable disease that can be converted to operable cases
  • Locoregional Tumor Control Rates [ Time Frame: 2 years ]
    Estimate 2-year locoregional tumor control rates, distant metastasis rates and overall survivial rates, as well as median overall survivial (OS)
  • Evaluation of EGFR Mutation Status and other genotypes [ Time Frame: 2 years ]
    Evaluate the status of various relevent genes such as EGFR, MET, and other genes that might be related to response or resistance to afatinib, and assess relationship to clinical outcomes
Same as current
Not Provided
Not Provided
Afatinib With CT and RT for EGFR-Mutant NSCLC
Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied and that study doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating different types of cancer. It also means that the FDA has not yet approved the drug for the patients type of cancer or for any use outside of research studies.

Chemotherapy and radiation is the standard treatment for the patients with stage III non-small cell lung cancer (NSCLC). For people with epidermal growth factor receptor (EGFR) mutations, adding a type of drug called a tyrosine kinase inhibitor (TKI) can help increase the response to treatment.

Afatinib is a tyrosine kinase inhibitor. It has been studied in a previous research study in participants with more advanced NSCLC. Results from that study indicate it may be helpful in treating NSCLC with EGFR mutations.

In this study, patients with stage III NSCLC and EGFR mutations will receive the standard treatment of radiation and chemotherapy. If possible, the patients tumor will be removed by surgery. Afatinib will be given before radiation and chemotherapy and after surgery. The aim of giving afatinib before radiation therapy is to try to shrink the tumor. This may make the radiation therapy more effective since radiation therapy tends to work better on smaller tumors.

The goal of this study is to see if adding afatinib to standard treatment helps to improve the response to treatment.

Study treatment will be divided into 5 stages:

Stage 1-induction, consisting of afatinib for two 4-week cycles. Afatinib is a pill that the patient takes by mouth once per day. The patient will receive a study drug diary in which to record the doses of afatinib.

Stage 2-concurrent radiation and chemotherapy with cisplatin/pemetrexed for two 3-week cycles.

Stage 3-Surgery to remove tumor for participants whose tumor can be removed by surgery. This will be done about 4-6 weeks after finishing radiation and chemotherapy. The exact timing will depend upon how quickly the patient recovers from side effects of the radiation and chemotherapy. The investigators will use a piece of the patients tumor removed by surgery for research tests to look for biomarkers such as genes and proteins that may be associated with response to afatinib, chemotherapy or radiation.

Stage 4-Chemotherapy after surgery (adjuvant chemotherapy). The patients doctor will decide if the patient will receive chemotherapy after the patients surgery but before receiving consolidation with afatinib. If the patient does receive this, it will start 6-12 weeks after surgery or finishing radiation if the patient does not have surgery. The chemotherapy will be the same as that received along with the radiation therapy.

Stage 5-Consolidation with afatinib for twenty-six 4-week cycles (2 years) for participants who responded to the 2 cycles of induction afatinib.

The investigators would like to keep track of the patients medical condition and status of the patients disease for up to 5 years after the patient stops study treatment. Keeping in touch with the patients and checking on the patients condition every year helps the investigators look at the long-term effects of the research study. The patients will be asked to have CT scans as follows:

  • Every 3 months for the first year after stopping study treatment
  • Every 6 months for years 2-4 after stopping study treatment
  • Once per year in year 5 after stopping study treatment
Phase 2
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Lung Cancer
  • Drug: Afatinib
    induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles
  • Radiation: Radiation
    Daily, Monday-Friday
  • Drug: Cisplatin
    Day 1 of each cycle, IV infusion over 60 minutes
  • Drug: Pemetrexed
    Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion
  • Procedure: Surgery
    Surgery to remove tumor
Experimental: Afatinib
  • Drug: Afatinib
  • Radiation: Radiation
  • Drug: Cisplatin
  • Drug: Pemetrexed
  • Procedure: Surgery
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2018
December 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed stage IIIA NSCLC
  • Measurable disease
  • Have lung cancer harboring an EGFR mutation
  • Must be evaluated by a medical oncologist, radiation oncologist and thoracic surgeon within 4 weeks of enrollment into study to document that they are a candidate for chemoradiation and for consideration of surgical resection (not required to be a surgical candidate)

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Prior EGFR TKI therapy
  • Prior treatment with radiation to the thoracic region (including breast irradiation)
  • Known pre-existing interstitial lung disease
  • Significant or recent gastrointestinal disorders with diarrhea as a major symptom
  • History or presence of relevant cardiovascular abnormalities
  • Any other concomitant serious illness or organ system dysfunction
  • Active hepatitis B, C or known HIV carrier
  • Known or suspected active drug or alcohol use
  • Known hypersensitivity to afatanib, cisplatin, or pemetrexed
  • Concomitant treatment with strong inhibitor of P-gp
  • History of an active malignancy within the last 3 years
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact: Lecia V Sequist, MD MPH 617-724-4000
United States
Not Provided
Not Provided
Lecia V. Sequist, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Principal Investigator: Lecia V Sequist, MD MPH Massachusetts General Hospital
Massachusetts General Hospital
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP